Arm 4

OTHER5 trials

Conditions

Carcinoma of Buccal MucosaGoutHIV/AIDSHIV/AIDS PaediatricsHead and Neck CancersHemiplegia And/or Hemiparesis Following StrokeOral Squamous Cell CarcinomaTongue Cancers

Phase 2

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

NCT02748707

Tata Memorial HospitalCarcinoma of Buccal Mucosa, Head and Neck Cancers, Oral Squamous Cell Carcinoma +1

Start: 2015-08-18End: 2023-04-30Updated: 2022-04-28

Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

CompletedNCT04804111

JW PharmaceuticalGout

Start: 2019-01-21End: 2020-11-29Updated: 2021-03-18

Phase 4

Pharmacy PrEP cRCT

Active, not recruitingPACTR202302662168727

jhpiegoHIV/AIDS

Start: 2023-04-01Target: 10800Updated: 2026-08-03

Unknown Phase

CHAPAS-2

Active, not recruitingPACTR201103000279108

Medical Research CouncilHIV/AIDS Paediatrics

Start: 2011-04-15Target: 64Updated: 2026-08-03

Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients

CompletedNCT04268641

Hôpital NOVOHemiplegia And/or Hemiparesis Following Stroke

Start: 2020-08-28End: 2023-12-11Updated: 2024-09-19

Related Papers

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study

Arthritis Research & Therapy2025-05-26

A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.